Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
The manager remains highly bullish on Liquidia due to the successful FDA approval and exceptional commercial launch of its flagship product, Yutrepia. Despite conservative analyst...
— Steven Kiel
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Liquidia Corp.
Liquidia was the fund's largest contributor in 2025. The fund holds...
Liquidia represents the manager's highest-conviction holding, with substantial upside driven by the successful launch of its Yutrepia product. Even under various...
Liquidia's commercial launch of Yutrepia has been highly successful, driving strong revenue growth. While the upcoming...
More institutional theses from Arquitos Capital Management
Liquidia was the fund's largest contributor in 2025. The fund holds...
The company recently reported excellent full-year results for 2025, showing significant growth in assets under management and revenue. Its adjusted EBITDA...
United Therapeutics is discussed strictly as Liquidia's key competitor and the opposing party in critical patent litigation. Its market multiple...